Ensuring Timely Access to Generics Act of 2019
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Ensuring Timely Access to Generics Act of 2019
This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.
The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.
The FDA may establish a timeline for submitting petitions.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 1169: Ensuring Timely Access to Generics Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-S-1169/
"S. 1169: Ensuring Timely Access to Generics Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-1169/.
S. 1169, 116th Cong. (2026), https://openamerica.io/bill/116-S-1169/.
[S. 1169: Ensuring Timely Access to Generics Act of 2019](https://openamerica.io/bill/116-S-1169/)